Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

Infection and Drug Resistance

Volumn 9, Issue , 2016, Pages 119-128

  Jones, Travis M ^a,b   Johnson, Steven W ^a,c   Dimondi, V Paul ^a,d   Wilson, Dustin T ^a,b  

^a CAMPBELL UNIVERSITY   (United States)

^b DUKE UNIVERSITY HOSPITAL   (United States)

^c FORSYTH MEDICAL CENTER   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

Author keywords

ABSSSI; CABP; Fluoroquinolone; JNJ Q2; MRSA

Indexed keywords

ACORAFLOXACIN; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NADIFLOXACIN; OFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TETRACYCLINE; VANCOMYCIN;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; CIPROFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS; COMMUNITY ACQUIRED PNEUMONIA; CONTACT DERMATITIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFUSION RELATED REACTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NONHUMAN; PHLEBITIS; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION;

EID: 84973472690     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S105620     Document Type: Review

References (47)

1. Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and beta-lactamase-inhibitor combination. Infect Drug Resist. 2013;6:215-223.
2. Mitra S, Saeed U, Havlichek DH, Stein GE. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections. Infect Drug Resist. 2015;8:189-197.
3. CDC [webpage on the Internet]. Antibiotic Resistance Threats in the United States, 2013. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed December 30, 2015.
4. Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014;22(8):438-445.
5. Covington P, Davenport JM, Andrae D, et al. Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother. 2011;55(12):5790-5797.
6. Biedenbach DJ, Farrell DJ, Flamm RK, Liverman LC, McIntyre G, Jones RN. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2012;39(4):321-325.
7. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and-resistant Staphylococcus aureus. J Infect Dis. 1991;163(6):1279-1285.
8. Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother. 2010;65(Suppl 4):iv17-iv31.
9. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147-159.
10. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-S72.
11. Tomic V, Dowzicky MJ. Regional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004-2008). Ann Clin Microbiol Antimicrob. 2014;13:52.
12. Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis. 2013;75(1):107-109.
13. Lee B, Boucher HW. Targeting antimicrobial-resistant bacterial respiratory tract pathogens: it is time to ‘get smart’. Curr Opin Pulm Med. 2015;21(3):293-303.
14. Morrow BJ, He W, Amsler KM, et al. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 2010;54(5):1955-1964.
15. Morrow BJ, Abbanat D, Baum EZ, et al. Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011;55(12):5512-5521.
16. Van Bambeke F. Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones. Ann Med. 2014;46(7):512-529.
17. Covington PS, Davenport JM, Andrae DA, et al. A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia. J Antimicrob Chemother. 2013;68(11):2691-2693.
18. Owens RC Jr., Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(Suppl 2):S144-S157.
19. Andriole VT. The quinolones: past, present, and future. Clin Infect Dis. 2005;41(Suppl 2):S113-S119.
20. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother. 1994;33(4):685-706.
21. Karpiuk I, Tyski S. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials. Przegl Epidemiol. 2013;67(3):455-460, 557-461.
22. Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A. 1997;94(25):13991-13996.
23. Farrell DJ, Liverman LC, Biedenbach DJ, Flamm RK, Jones RN. Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic Streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2011;71(4):415-420.
24. Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother. 2011;55(7):3631-3634.
25. Fernandez J, Hilliard JJ, Morrow BJ, et al. Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections. Antimicrob Agents Chemother. 2011;55(12):5522-5528.
26. Kaatz GW, Moudgal VV, Seo SM. Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J Antimicrob Chemother. 2002;50(6):833-838.
27. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem. 2003;3(3):249-282.
28. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(5):1604-1613.
29. Davenport JM, Covington P, Gotfried M, et al. Summary of pharmacokinetics and tissue distribution of a broad-spectrum fluoroquinolone, JNJ-Q2. Clin Pharmacol Drug Dev. 2012;1(4):121-130.
30. Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a oncedaily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother. 1999;43(11):2793-2797.
31. Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 1998;42(8):2060-2065.
32. Labreche MJ, Frei CR. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes. Am J Health Syst Pharm. 2012;69(21):1863-1870.
33. Eichenbaum G, Pugsley MK, Gallacher DJ, et al. Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2. Br J Pharmacol. 2012;166(5):1694-1707.
34. Corey GR, Stryjewski ME. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Clin Infect Dis. 2011;52 (Suppl 7):S469-S476.
35. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-674.
36. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15(9):1516-1518.
37. Pallin DJ, Espinola JA, Leung DY, Hooper DC, Camargo CA Jr. Epidemiology of dermatitis and skin infections in United States physicians’ offices, 1993-2005. Clin Infect Dis. 2009;49(6):901-907.
38. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51(26):565-567.
39. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol. 2006;44(2):655-656.
40. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303(22):2260-2264.
41. Jain S, Self WH, Wunderink RG, et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427.
42. Biedenbach DJ, Turner LL, Jones RN, Farrell DJ. Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. Diagn Microbiol Infect Dis. 2012;74(2):204-206.
43. LeBel M, Vallee F, Bergeron MG. Tissue penetration of ciprofloxacin after single and multiple doses. Antimicrob Agents Chemother. 1986;29(3):501-505.
44. Gonzalez MA, Moranchel AH, Duran S, et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother. 1985;28(2):235-239.
45. Sorgel F, Naber KG, Kinzig M, Mahr G, Muth P. Comparative pharma­cokinetics of ciprofloxacin and temafloxacin in humans: a review. Am J Med. 1991;91(6A):51S-66S.
46. Holland M, Chien SC, Corrado M, Flor SC, Rogge MC. The pharmacokinetic profile of levofloxacin following once- or twice-daily 500mg administration. Poster presented at: Fifth International Symposium on New Quinolones; August 25-27, 1994; Singapore.
47. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999;43(Suppl B):83-90.